Unknown

Dataset Information

0

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

ABSTRACT: [This corrects the article DOI: 10.18632/oncotarget.4318.].

SUBMITTER: Goldenberg DM 

PROVIDER: S-EPMC7075468 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg David M DM   Cardillo Thomas M TM   Govindan Serengulam V SV   Rossi Edmund A EA   Sharkey Robert M RM  

Oncotarget 20200310 10

[This corrects the article DOI: 10.18632/oncotarget.4318.]. ...[more]

Similar Datasets

Unknown Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
| S-EPMC4673178 | biostudies-literature
Unknown Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
| S-EPMC5559902 | biostudies-literature
Unknown Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
| S-EPMC7007291 | biostudies-literature
Unknown Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.
| S-EPMC6030029 | biostudies-literature
Unknown Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
| S-EPMC7303962 | biostudies-literature
Unknown First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
| S-EPMC4558321 | biostudies-literature
Unknown Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
| S-EPMC6976591 | biostudies-literature
Unknown Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
| S-EPMC6748572 | biostudies-literature
Unknown Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
| S-EPMC7597411 | biostudies-literature
Unknown Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
| S-EPMC7028697 | biostudies-literature